New TNM melanoma staging system: Linking biology and natural history to clinical outcomes
The American Joint Committee on Cancer (AJCC) implemented major revisions of the melanoma TNM and stage grouping criteria in the recently published 6th edition of the Staging Manual. The new staging system better reflects independent prognostic factors that are used in clinical trials and in reporti...
Gespeichert in:
| Veröffentlicht in: | Seminars in surgical oncology 2003, Vol.21 (1), p.43-52 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52 |
|---|---|
| container_issue | 1 |
| container_start_page | 43 |
| container_title | Seminars in surgical oncology |
| container_volume | 21 |
| creator | Balch, Charles M. Buzaid, Antonio C. Soong, Seng-Jaw Atkins, Michael B. Cascinelli, Natale Coit, Daniel G. Fleming, Irvin D. Gershenwald, Jeffrey E. Houghton Jr, Alan Kirkwood, John M. McMasters, Kelly M. Mihm, Martin F. Morton, Donald L. Reintgen, Douglas S. Ross, Merrick I. Sober, Arthur Thompson, John A. Thompson, John F. |
| description | The American Joint Committee on Cancer (AJCC) implemented major revisions of the melanoma TNM and stage grouping criteria in the recently published 6th edition of the Staging Manual. The new staging system better reflects independent prognostic factors that are used in clinical trials and in reporting the outcomes of various melanoma treatment modalities. Major revisions include: 1) melanoma thickness and ulceration but not level of invasion to be used in the T classification, 2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of microscopic vs. macroscopic nodal metastases to be used in the N classification, 3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase (LDH) to be used in the M classification, 4) an upstaging of all patients with Stage I, II, and III disease when a primary melanoma is ulcerated, 5) a merging of satellite metastases around a primary melanoma and in transit metastases into a single staging entity that is grouped into Stage III disease, and 6) a new convention for defining clinical and pathological staging so as to take into account the new staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. Semin. Surg. Oncol. 21:43–52, 2003. © 2003 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ssu.10020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73565442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73565442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2760-4a942aed997e3c85f5191cc591eb32006e32ecec986d99f46aeea65fa1e785833</originalsourceid><addsrcrecordid>eNp1kEtPwzAQhC0EgvI48AeQT0gcAn7Eic0NKl5SKUK0Ak6W626KIYlLnKjk3xNogROnnV19M9IOQvuUHFNC2EkIzbcga6hHiZIR41Kuo55MRRKRmKdbaDuEV0IoFYxvoi3KFOOKih56HsICj4a3uIDclL4wONRm5soZDm2ooTjFA1e-fe0T53M_a7Epp7g0dVOZHL-4UPuqxbXHNnels93NN7X1BYRdtJGZPMDeau6g8eXFqH8dDe6ubvpng8iyNCFRbFTMDEyVSoFbKTJBFbVWKAoTzghJgDOwYJVMOiaLEwNgEpEZCqkUkvMddLjMnVf-vYFQ68IFC3n3Dvgm6JSLRMQx68CjJWgrH0IFmZ5XrjBVqynRX_XprsdvQTr2YBXaTAqY_pGr4jrgZAksXA7t_0n64WH8ExktHV1n8PHrMNWbTlKeCv04vNL9J0nOyf1AU_4JwKyMKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73565442</pqid></control><display><type>article</type><title>New TNM melanoma staging system: Linking biology and natural history to clinical outcomes</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Balch, Charles M. ; Buzaid, Antonio C. ; Soong, Seng-Jaw ; Atkins, Michael B. ; Cascinelli, Natale ; Coit, Daniel G. ; Fleming, Irvin D. ; Gershenwald, Jeffrey E. ; Houghton Jr, Alan ; Kirkwood, John M. ; McMasters, Kelly M. ; Mihm, Martin F. ; Morton, Donald L. ; Reintgen, Douglas S. ; Ross, Merrick I. ; Sober, Arthur ; Thompson, John A. ; Thompson, John F.</creator><creatorcontrib>Balch, Charles M. ; Buzaid, Antonio C. ; Soong, Seng-Jaw ; Atkins, Michael B. ; Cascinelli, Natale ; Coit, Daniel G. ; Fleming, Irvin D. ; Gershenwald, Jeffrey E. ; Houghton Jr, Alan ; Kirkwood, John M. ; McMasters, Kelly M. ; Mihm, Martin F. ; Morton, Donald L. ; Reintgen, Douglas S. ; Ross, Merrick I. ; Sober, Arthur ; Thompson, John A. ; Thompson, John F.</creatorcontrib><description>The American Joint Committee on Cancer (AJCC) implemented major revisions of the melanoma TNM and stage grouping criteria in the recently published 6th edition of the Staging Manual. The new staging system better reflects independent prognostic factors that are used in clinical trials and in reporting the outcomes of various melanoma treatment modalities. Major revisions include: 1) melanoma thickness and ulceration but not level of invasion to be used in the T classification, 2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of microscopic vs. macroscopic nodal metastases to be used in the N classification, 3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase (LDH) to be used in the M classification, 4) an upstaging of all patients with Stage I, II, and III disease when a primary melanoma is ulcerated, 5) a merging of satellite metastases around a primary melanoma and in transit metastases into a single staging entity that is grouped into Stage III disease, and 6) a new convention for defining clinical and pathological staging so as to take into account the new staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. Semin. Surg. Oncol. 21:43–52, 2003. © 2003 Wiley‐Liss, Inc.</description><identifier>ISSN: 8756-0437</identifier><identifier>EISSN: 1098-2388</identifier><identifier>DOI: 10.1002/ssu.10020</identifier><identifier>PMID: 12923915</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Clinical Trials as Topic - methods ; Humans ; Lymphatic Metastasis ; melanoma ; Melanoma - classification ; Melanoma - diagnosis ; Melanoma - mortality ; Melanoma - secondary ; Melanoma - therapy ; Neoplasm Invasiveness ; Neoplasm Staging - methods ; Neoplasm Staging - trends ; Predictive Value of Tests ; prognosis ; Sentinel Lymph Node Biopsy - classification ; Sentinel Lymph Node Biopsy - methods ; Skin Neoplasms - classification ; Skin Neoplasms - diagnosis ; Skin Neoplasms - mortality ; Skin Neoplasms - therapy ; staging ; Survival Rate ; Treatment Outcome</subject><ispartof>Seminars in surgical oncology, 2003, Vol.21 (1), p.43-52</ispartof><rights>Copyright © 2003 Wiley‐Liss, Inc., A Wiley Company</rights><rights>Copyright 2003 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2760-4a942aed997e3c85f5191cc591eb32006e32ecec986d99f46aeea65fa1e785833</citedby><cites>FETCH-LOGICAL-c2760-4a942aed997e3c85f5191cc591eb32006e32ecec986d99f46aeea65fa1e785833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fssu.10020$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fssu.10020$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12923915$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balch, Charles M.</creatorcontrib><creatorcontrib>Buzaid, Antonio C.</creatorcontrib><creatorcontrib>Soong, Seng-Jaw</creatorcontrib><creatorcontrib>Atkins, Michael B.</creatorcontrib><creatorcontrib>Cascinelli, Natale</creatorcontrib><creatorcontrib>Coit, Daniel G.</creatorcontrib><creatorcontrib>Fleming, Irvin D.</creatorcontrib><creatorcontrib>Gershenwald, Jeffrey E.</creatorcontrib><creatorcontrib>Houghton Jr, Alan</creatorcontrib><creatorcontrib>Kirkwood, John M.</creatorcontrib><creatorcontrib>McMasters, Kelly M.</creatorcontrib><creatorcontrib>Mihm, Martin F.</creatorcontrib><creatorcontrib>Morton, Donald L.</creatorcontrib><creatorcontrib>Reintgen, Douglas S.</creatorcontrib><creatorcontrib>Ross, Merrick I.</creatorcontrib><creatorcontrib>Sober, Arthur</creatorcontrib><creatorcontrib>Thompson, John A.</creatorcontrib><creatorcontrib>Thompson, John F.</creatorcontrib><title>New TNM melanoma staging system: Linking biology and natural history to clinical outcomes</title><title>Seminars in surgical oncology</title><addtitle>Semin. Surg. Oncol</addtitle><description>The American Joint Committee on Cancer (AJCC) implemented major revisions of the melanoma TNM and stage grouping criteria in the recently published 6th edition of the Staging Manual. The new staging system better reflects independent prognostic factors that are used in clinical trials and in reporting the outcomes of various melanoma treatment modalities. Major revisions include: 1) melanoma thickness and ulceration but not level of invasion to be used in the T classification, 2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of microscopic vs. macroscopic nodal metastases to be used in the N classification, 3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase (LDH) to be used in the M classification, 4) an upstaging of all patients with Stage I, II, and III disease when a primary melanoma is ulcerated, 5) a merging of satellite metastases around a primary melanoma and in transit metastases into a single staging entity that is grouped into Stage III disease, and 6) a new convention for defining clinical and pathological staging so as to take into account the new staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. Semin. Surg. Oncol. 21:43–52, 2003. © 2003 Wiley‐Liss, Inc.</description><subject>Clinical Trials as Topic - methods</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>melanoma</subject><subject>Melanoma - classification</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - mortality</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging - methods</subject><subject>Neoplasm Staging - trends</subject><subject>Predictive Value of Tests</subject><subject>prognosis</subject><subject>Sentinel Lymph Node Biopsy - classification</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><subject>Skin Neoplasms - classification</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - therapy</subject><subject>staging</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>8756-0437</issn><issn>1098-2388</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtPwzAQhC0EgvI48AeQT0gcAn7Eic0NKl5SKUK0Ak6W626KIYlLnKjk3xNogROnnV19M9IOQvuUHFNC2EkIzbcga6hHiZIR41Kuo55MRRKRmKdbaDuEV0IoFYxvoi3KFOOKih56HsICj4a3uIDclL4wONRm5soZDm2ooTjFA1e-fe0T53M_a7Epp7g0dVOZHL-4UPuqxbXHNnels93NN7X1BYRdtJGZPMDeau6g8eXFqH8dDe6ubvpng8iyNCFRbFTMDEyVSoFbKTJBFbVWKAoTzghJgDOwYJVMOiaLEwNgEpEZCqkUkvMddLjMnVf-vYFQ68IFC3n3Dvgm6JSLRMQx68CjJWgrH0IFmZ5XrjBVqynRX_XprsdvQTr2YBXaTAqY_pGr4jrgZAksXA7t_0n64WH8ExktHV1n8PHrMNWbTlKeCv04vNL9J0nOyf1AU_4JwKyMKg</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Balch, Charles M.</creator><creator>Buzaid, Antonio C.</creator><creator>Soong, Seng-Jaw</creator><creator>Atkins, Michael B.</creator><creator>Cascinelli, Natale</creator><creator>Coit, Daniel G.</creator><creator>Fleming, Irvin D.</creator><creator>Gershenwald, Jeffrey E.</creator><creator>Houghton Jr, Alan</creator><creator>Kirkwood, John M.</creator><creator>McMasters, Kelly M.</creator><creator>Mihm, Martin F.</creator><creator>Morton, Donald L.</creator><creator>Reintgen, Douglas S.</creator><creator>Ross, Merrick I.</creator><creator>Sober, Arthur</creator><creator>Thompson, John A.</creator><creator>Thompson, John F.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2003</creationdate><title>New TNM melanoma staging system: Linking biology and natural history to clinical outcomes</title><author>Balch, Charles M. ; Buzaid, Antonio C. ; Soong, Seng-Jaw ; Atkins, Michael B. ; Cascinelli, Natale ; Coit, Daniel G. ; Fleming, Irvin D. ; Gershenwald, Jeffrey E. ; Houghton Jr, Alan ; Kirkwood, John M. ; McMasters, Kelly M. ; Mihm, Martin F. ; Morton, Donald L. ; Reintgen, Douglas S. ; Ross, Merrick I. ; Sober, Arthur ; Thompson, John A. ; Thompson, John F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2760-4a942aed997e3c85f5191cc591eb32006e32ecec986d99f46aeea65fa1e785833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Clinical Trials as Topic - methods</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>melanoma</topic><topic>Melanoma - classification</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - mortality</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging - methods</topic><topic>Neoplasm Staging - trends</topic><topic>Predictive Value of Tests</topic><topic>prognosis</topic><topic>Sentinel Lymph Node Biopsy - classification</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><topic>Skin Neoplasms - classification</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - therapy</topic><topic>staging</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balch, Charles M.</creatorcontrib><creatorcontrib>Buzaid, Antonio C.</creatorcontrib><creatorcontrib>Soong, Seng-Jaw</creatorcontrib><creatorcontrib>Atkins, Michael B.</creatorcontrib><creatorcontrib>Cascinelli, Natale</creatorcontrib><creatorcontrib>Coit, Daniel G.</creatorcontrib><creatorcontrib>Fleming, Irvin D.</creatorcontrib><creatorcontrib>Gershenwald, Jeffrey E.</creatorcontrib><creatorcontrib>Houghton Jr, Alan</creatorcontrib><creatorcontrib>Kirkwood, John M.</creatorcontrib><creatorcontrib>McMasters, Kelly M.</creatorcontrib><creatorcontrib>Mihm, Martin F.</creatorcontrib><creatorcontrib>Morton, Donald L.</creatorcontrib><creatorcontrib>Reintgen, Douglas S.</creatorcontrib><creatorcontrib>Ross, Merrick I.</creatorcontrib><creatorcontrib>Sober, Arthur</creatorcontrib><creatorcontrib>Thompson, John A.</creatorcontrib><creatorcontrib>Thompson, John F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balch, Charles M.</au><au>Buzaid, Antonio C.</au><au>Soong, Seng-Jaw</au><au>Atkins, Michael B.</au><au>Cascinelli, Natale</au><au>Coit, Daniel G.</au><au>Fleming, Irvin D.</au><au>Gershenwald, Jeffrey E.</au><au>Houghton Jr, Alan</au><au>Kirkwood, John M.</au><au>McMasters, Kelly M.</au><au>Mihm, Martin F.</au><au>Morton, Donald L.</au><au>Reintgen, Douglas S.</au><au>Ross, Merrick I.</au><au>Sober, Arthur</au><au>Thompson, John A.</au><au>Thompson, John F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New TNM melanoma staging system: Linking biology and natural history to clinical outcomes</atitle><jtitle>Seminars in surgical oncology</jtitle><addtitle>Semin. Surg. Oncol</addtitle><date>2003</date><risdate>2003</risdate><volume>21</volume><issue>1</issue><spage>43</spage><epage>52</epage><pages>43-52</pages><issn>8756-0437</issn><eissn>1098-2388</eissn><abstract>The American Joint Committee on Cancer (AJCC) implemented major revisions of the melanoma TNM and stage grouping criteria in the recently published 6th edition of the Staging Manual. The new staging system better reflects independent prognostic factors that are used in clinical trials and in reporting the outcomes of various melanoma treatment modalities. Major revisions include: 1) melanoma thickness and ulceration but not level of invasion to be used in the T classification, 2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of microscopic vs. macroscopic nodal metastases to be used in the N classification, 3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase (LDH) to be used in the M classification, 4) an upstaging of all patients with Stage I, II, and III disease when a primary melanoma is ulcerated, 5) a merging of satellite metastases around a primary melanoma and in transit metastases into a single staging entity that is grouped into Stage III disease, and 6) a new convention for defining clinical and pathological staging so as to take into account the new staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. Semin. Surg. Oncol. 21:43–52, 2003. © 2003 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12923915</pmid><doi>10.1002/ssu.10020</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 8756-0437 |
| ispartof | Seminars in surgical oncology, 2003, Vol.21 (1), p.43-52 |
| issn | 8756-0437 1098-2388 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73565442 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Clinical Trials as Topic - methods Humans Lymphatic Metastasis melanoma Melanoma - classification Melanoma - diagnosis Melanoma - mortality Melanoma - secondary Melanoma - therapy Neoplasm Invasiveness Neoplasm Staging - methods Neoplasm Staging - trends Predictive Value of Tests prognosis Sentinel Lymph Node Biopsy - classification Sentinel Lymph Node Biopsy - methods Skin Neoplasms - classification Skin Neoplasms - diagnosis Skin Neoplasms - mortality Skin Neoplasms - therapy staging Survival Rate Treatment Outcome |
| title | New TNM melanoma staging system: Linking biology and natural history to clinical outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A56%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20TNM%20melanoma%20staging%20system:%20Linking%20biology%20and%20natural%20history%20to%20clinical%20outcomes&rft.jtitle=Seminars%20in%20surgical%20oncology&rft.au=Balch,%20Charles%20M.&rft.date=2003&rft.volume=21&rft.issue=1&rft.spage=43&rft.epage=52&rft.pages=43-52&rft.issn=8756-0437&rft.eissn=1098-2388&rft_id=info:doi/10.1002/ssu.10020&rft_dat=%3Cproquest_cross%3E73565442%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73565442&rft_id=info:pmid/12923915&rfr_iscdi=true |